This indicates that patients with both L858R and TP53 mutations should be advised to combine chemotherapy or antiangiogenic drugs with osimertinib, or even consider using all of these treatments together in T790M‐mutated NSCLC. The gene discussed is TP53; the disease is non-small cell lung carcinoma.